Atglistatin is an inhibitor of adipose triglyceride lipase (ATGL) that decreases fatty acid mobilization and prevents lipolysis. Atglistatin also prevents triglyceride accumulation after acute myocardial infarction, displaying cardioprotective benefit.
| Cas No. | 1469924-27-3 |
|---|---|
| Purity | ≥98% |
| Formula | C17H21N3O |
| Formula Wt. | 283.38 |
| IUPAC Name | 3-[4'-(Dimethylamino)-3-biphenylyl]-1,1-dimethylurea |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | A7725 Info Sheet PDF |
|---|
Zhang H, Sun T, Jiang X, et al. PEDF and PEDF-derived peptide 44mer stimulate cardiac triglyceride degradation via ATGL. J Transl Med. 2015 Feb 21;13:68. PMID: 25890298.
Cerk IK, Salzburger B, Boeszoermenyi A, et al. A peptide derived from G0/G1 switch gene 2 acts as noncompetitive inhibitor of adipose triglyceride lipase. J Biol Chem. 2014 Nov 21;289(47):32559-70. PMID: 25258314.
Mayer N, Schweiger M, Romauch M, et al. Development of small-molecule inhibitors targeting adipose triglyceride lipase. Nat Chem Biol. 2013 Dec;9(12):785-7. PMID: 24096302.
